Jenny Zilberberg

Company: Imvax Inc.

Job title: Head of Research

Seminars:

The GoldspireTM Platform: A Personalized Biologic-Device Combination Approach to Generate Innate & Adaptive Anti-Tumor Immunity via Immunogenic Cell Death Mechanisms 3:30 pm

Positive results seen in Phase 1b GBM trial Phase 2b study is recruiting Immunogenic cell death-associated markers in combination with evidence of anti-tumor immune responses in murine models and patient samples supports the underlying mechanism of action of GoldspireTMRead more

day: Conference Day Two